Stem Cell Transplant for Immunologic or Histiocytic Disorders
| Status: | Completed |
|---|---|
| Conditions: | Other Indications, Infectious Disease, HIV / AIDS, Hematology |
| Therapuetic Areas: | Hematology, Immunology / Infectious Diseases, Other |
| Healthy: | No |
| Age Range: | Any - 35 |
| Updated: | 12/30/2017 |
| Start Date: | August 2002 |
| End Date: | August 2014 |
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism
This study tests the clinical outcomes of a preparative regimen of fludarabine (FLU),
anti-thymocyte globulin (ATG)/or Campath, and melphalan; followed by hematopoietic stem cell
transplant, and a post transplant regimen of Cyclosporin A (CsA) in patients with immunologic
or histiocytic disorders. The researchers hypothesize that this regimen will have a positive
effect on post transplant engraftment and the incidence of graft-versus-host-disease (GVHD).
Patients will be randomized biologically into one of 3 arms based upon donor availability:
(a) human leukocyte antigen (HLA) genotypic matched sibling donor, (b) HLA phenotypic matched
unrelated peripheral blood stem cell (PBSC) donor, (c) two HLA 0-2 antigen mismatched
unrelated cord blood donors (double cord).
anti-thymocyte globulin (ATG)/or Campath, and melphalan; followed by hematopoietic stem cell
transplant, and a post transplant regimen of Cyclosporin A (CsA) in patients with immunologic
or histiocytic disorders. The researchers hypothesize that this regimen will have a positive
effect on post transplant engraftment and the incidence of graft-versus-host-disease (GVHD).
Patients will be randomized biologically into one of 3 arms based upon donor availability:
(a) human leukocyte antigen (HLA) genotypic matched sibling donor, (b) HLA phenotypic matched
unrelated peripheral blood stem cell (PBSC) donor, (c) two HLA 0-2 antigen mismatched
unrelated cord blood donors (double cord).
Prior to transplantation, subjects will receive Melphalan, Fludarabine and Anti-Thymocyte
Globulin (ATG) or Campath. These three drugs are being given to subjects to help the new stem
cells take and grow. On the day of transplantation, subjects will receive stem cells
transfused via intravenous (IV) catheter.
After stem cell transplantation, subjects will be given Cyclosporin A (CsA) and mycophenolate
mofetil (MMF) to reduce the risk of graft-versus-host disease, the complication that occurs
when the donor's stem cells react against the patient.
Globulin (ATG) or Campath. These three drugs are being given to subjects to help the new stem
cells take and grow. On the day of transplantation, subjects will receive stem cells
transfused via intravenous (IV) catheter.
After stem cell transplantation, subjects will be given Cyclosporin A (CsA) and mycophenolate
mofetil (MMF) to reduce the risk of graft-versus-host disease, the complication that occurs
when the donor's stem cells react against the patient.
Inclusion Criteria:
Patients with immunodeficiencies or histiocytic disorders 0-35 years of age with an
acceptable stem cell donor and disease characteristic defined by the following:
- Patients with histocytic disorders (hemophagocytic lymphohistiocytosis of any etiology
and refractory Langerhans cell histiocytosis) who do not meet eligibility criteria for
a myeloablative transplant procedure
- Patients with immunodeficiency disorders in whom residual immune function may not
require a fully myeloablative preparative regimen or patient is ineligible for
standard myeloablative preparative regimen (any form of severe combined
immunodeficiency [SCID], or other immunodeficiency with T cell defect)
- Patients with immunodeficiency disorders that have had poor outcome with myeloablative
stem cell transplants (including, but not limited to, common variable immunodeficiency
[CVID], Wiskott Aldrich Syndrome [WAS] if > 5 years of age, ataxia telangiectasia)
- Patients with immunodeficiencies or histocytic disorders that require a second stem
cell transplant (SCT) for any reason
Exclusion Criteria:
- Karnofsky or Lansky performance score <70
- Glomerular filtration rate (GFR)<30% predicted
- Cardiac function <50% normal by echocardiogram
- Serum creatinine > 2x normal for age/weight
- Pregnant or lactating females
- Active serious infection that has not had an adequate course of therapy pre-SCT. Any
patient with acquired immune deficiency syndrome (AIDS) or AIDS-related complex (ARC)
or human immunodeficiency virus (HIV) seropositivity
We found this trial at
1
site
425 E River Pkwy # 754
Minneapolis, Minnesota 55455
Minneapolis, Minnesota 55455
612-624-2620
Masonic Cancer Center at University of Minnesota The Masonic Cancer Center was founded in 1991....
Click here to add this to my saved trials
